Promising prostate cancer drug gets extended trial for those already benefiting
NCT ID NCT04145375
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial gives men with metastatic castration-resistant prostate cancer (mCRPC) continued access to the experimental drug ZEN003694, often combined with enzalutamide (Xtandi), if they are already seeing benefits from it in a previous study. About 40 participants will be enrolled to monitor side effects and long-term outcomes like tumor response and survival. The goal is to keep providing a potentially helpful treatment while gathering more safety data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZEN003694 (a drug) and enzalutamide (Xtandi)
What this could lead to
If successful, this could offer a way for men with advanced prostate cancer to keep receiving a promising treatment that is helping them.
What could go wrong
This is an early-phase continuation study with only 40 participants, so results may not apply broadly. Side effects are possible, and the drug is still investigational.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
University of California San Francisco Medical Center
San Francisco, California, 94104, United States